First Trust BuyWrite Income ETF

Most Recent

  • uploads///Chart
    Company & Industry Overviews

    Understanding Sanofi’s 3Q17 Performance by Business Segment

    Sanofi now reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur (or the Human Vaccines segment).

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyst Ratings and Recommendations for Sanofi

    In 4Q17, Sanofi reported earnings per share of 1.06 euros on revenues of 8.7 billion euros.

    By Mike Benson
  • uploads///ABLYNX_TRANSACTION_HIGHLIGHTS
    Company & Industry Overviews

    Why Sanofi Has Received a Negative Outlook from Fitch Ratings

    Fitch Ratings views Sanofi’s two recent acquisitions in close succession with a total value of 13.7 billion euros as a risk to its balance sheet.

    By Sarah Collins
  • uploads///PROPHYLAXIS
    Company & Industry Overviews

    Sanofi Leads the Hemophilia Space on Bioverativ Acquisition

    According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

    By Sarah Collins
  • uploads///Chart
    Company & Industry Overviews

    How Gilead’s Revenue Trended in 2016

    Gilead Sciences (GILD) reported a decrease in revenues by ~7% to $30.4 billion during 2016 as compared to $32.6 billion during 2015.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.